ScanGrants is a public service listing of grants and other funding types to support health research, programs and scholarship.
11 funding opportunities found in this category. Change the order of results:
Lowest Award to Highest
Highest Award to Lowest
CHEST Foundation 2014 Grants and Awards Program
Each year, The CHEST Foundation offers CHEST members grants for clinical and translational research, leadership, and volunteer community service. Nearly 800 recipients worldwide have received more than $9 million to support and recognize outstanding work in chest medicine.
Application deadline: May 31
For more information, contact:
Dr. Sydney Parker, Director, Grants and Awards
Distinguished Scholar in Thrombosis Grant
GlaxoSmithKline Distinguished Scholar in Thrombosis
$150,000 awarded over 3 years
Application Deadline: May 31
The Distinguished Scholar in Thrombosis grant supports clinical educational projects to improve patient care and is intended for the investigation of issues that are not easily supported through traditional funding. The grant will support a Fellow of the American College of CHEST Physicians (FCCP) who is a recognized clinician and/or scientist with a specialty in thrombosis as evidenced by publications, presentations, and peers. The applicant must propose a thrombosis-related project that does one or more of the following:
• Investigates alternatives for treatment.
• Educates patients about options for diagnosis and treatment.
• Disseminates new knowledge about diagnosis and treatment.
• Defines new mechanisms leading to innovations and improvements to treatment.
Clinical Research Grants and Leadership Awards
The CHEST Foundation Clinical Research Grant in Lung Cancer
$100,000 awarded over 2 years
Application Deadline: May 31, 2014
This grant, establashed through a grant from Genetech, supports a clinical/translational research project that could lead to improved treatment and/or cure for lung cancer. Applicant must be a CHEST member who has completed at least 1 year of a pulmonary or critical care fellowship or a thoracic surgery residency and be within 7 years of completing training.
The CHEST Foundation Clinical Research Grant in Pulmonary Arterial Hypertension
$50,000 (July 2014 to June 2015)
This grant, established through a grant from Actelion Pharmaceuticals, US, Inc., supports a clinical/translational research project that contributes to the understanding of the pathophysiology or treatment of pulmonary arterial hypertension. Research must be completed between July 2014 and June 2015. Applicant must be a CHEST member who has completed at least 1 year of a pulmonary or critical care fellowship and be within 7 years of completing training.
The CHEST Foundation and The Pulmonary Fibrosis Foundation Clinical Research Grant in Pulmonary Fibrosis
$30,000 (July 2014 to June 2015)
This grant supports a clinical/translational research project that contributes to effective treatments or a cure for pulmonary fibrosis. Research must be completed between July 2014 and June 2015. Applicant must be a CHEST member who has completed at least 1 year of a pulmonary or critical care fellowship and be within 7 years of completing training.
Diversity Committee Young Investigator Faculty Scholar in Pulmonary, Cardiovascular, Critical Care, or Sleep Research Grant
$25,000 (July 2014 to June 2015)
This grant supports outstanding underrepresented young investigators in their careers in pulmonary, cardiovascular, critical care, or sleep research, with a focus on promoting equity and reducing disparity within a global setting. The grant supports clinical/translational research in pulmonary, cardiovascular, critical care, or sleep medicine. Research must be completed between July 2014 and June 2015.
Applicant must be a CHEST member who has completed at least 1 year of a pulmonary or critical care fellowship and be within 5 years of completing training.
The CHEST Foundation and Alpha-1 Foundation Clinical Research Grant in COPD and Alpha-1 Antitrypsin (AAT) Deficiency
This award supports research focused on COPD and AAT deficiency. While research projects primarily in usual COPD (not associated with AAT deficiency) are allowed, those with a focus on AAT deficiency are encouraged. Research must be completed between July 2014 and June 2015. Applicant must be a CHEST member who qualifies as a young investigator (ie, in an ACGME fellowship training programs and within 5 years of completion).
The CHEST Foundation and Respiratory Health Association Clinical Research Grant in Women’s Lung Health
$10,000 (July 2014 to June 2015)
This grant supports a clinical research project related to women’s lung health. Topics may include research on gender differences in lung diseases, such as COPD and lung cancer. Research must be completed between July 1, 2014 and June 30, 2015.
Applicant must be a CHEST member and hold the degree of MD, DO, MBBCh, PharmD, PhD, or the equivalent.
Community Service and Humanitarian Grants
McCaffree Community Service and Humanitarian Grants
$5,000 to $15,000
The McCaffree Community Service and Humanitarian grants are given for community-based projects supported by the service work of CHEST members worldwide. Projects must show a clear impact on the community and have the potential for long-term sustainability and replicability. Grant funds are paid to the nonprofit or nongovernmental organization where the member donates time and medical service.
Call for Applications: Alex's Lemonade Stand Foundation Bio-Therapeutics Impact Award
Application due date: June 12, 2014 (11:59 PM ET)
All requests must be submitted using ALSF’s online application.
Alex’s Lemonade Stand Foundation evolved from a young cancer patient’s front yard lemonade stand to a national foundation for childhood cancer.
The Bio-Therapeutics Impact Award accelerates the development of clinical trials for promising biologic approaches to treating childhood cancer. These approaches include, but are not limited to, immunotherapy, gene therapy and small molecules. The award, intended for investigators who are initiating clinical trials or undertaking the pre-clinical work necessary to move into the IND (investigational new drug) phase, totals the maximum of $1.5 million awarded over three years.
Call for Applications: PhRMA Foundation Assessing the Benefits of Treating Cancer Research Starter Grant
Opening Date: March 2014
Closing Date: May 16, 2014
Anticipated Award Date: July 2014
Researchers and clinicians have made remarkable progress in the fight against cancer, and death rates are falling. However, the disease still causes enormous suffering and represents a substantial economic burden in the United States. While cancer medicines have extended millions of lives and offer trillions in societal benefits, this value often is not well understood or fully characterized. Social and economic benefits accrue across a range of direct and indirect effects (e.g., overall survival, quality of life, and productivity) and evolve over time as the body of evidence and standards of practice change. As our understanding of the basic science of cancer grows, and this understanding is translated into novel diagnostics and treatments, patients and society benefit from continual innovation in cancer care. The purpose of this RFP is to encourage research aimed at quantifying the benefits to society that have accrued from innovations in cancer treatment.
The grant will be awarded to candidates who establish a sound and innovative research project focused on developing a novel way of quantifying or describing the social, patient-centered, and economic benefits of innovation in cancer treatment. Relevant research goals may include developing new methods to define and measure the societal benefits from cancer care innovation (for example, contributing to an understanding of value across a wider range of outputs that can be more difficult to assess, capturing heterogeneity in patient values (such as quality of life, productivity, etc.) within and among populations, and accounting for variability in value over time and its relationship to long-term aggregate clinical gains against cancer). Examples of the types of research questions of interest include:
-- Developing a novel way of describing the benefits of treatments that accrue over time as clinicians develop a better understanding of the disease process and treatment protocols. Oftentimes, patients who are enrolled in clinical trials are in later stages of the disease; however, once a drug is approved, it may be used at an earlier stage. Thus, the benefits of treatment may not be fully realized for several years after approval.
-- Describing improvements in quality of life, productivity, or other patient-centered measures that can result from cancer treatment. Patients may value certain outcomes and benefits differently than other stakeholders; describing the heterogeneity of value across the range of stakeholders (including patients, caregivers, providers, etc) is an important step to developing a fuller picture of treatment gains beyond the traditionally reported 5- and 10-year survival rates.
-- Building a more complete picture of innovation in cancer research and treatment over time. Most scientific progress builds on earlier research and development. Scientific understanding of cancer has grown from viewing the condition as a single monolithic disease to a constellation of hundreds of different molecular pathways. As scientists elucidate these pathways, there are spillover benefits as this increased understanding of the molecular basis of disease can result in advances in other areas.
This award is not intended for clinical or bench research, and is focused on supporting research in the health economics and social science fields. Additionally, research results should be generalizable to the U.S. context. Proposals focused on methods are eligible; however, researchers must clearly indicate how these new methods will be used to capture patient, population, or societal outcomes and benefits.
Individuals holding a rank of instructor, assistant professor, or investigator at the doctoral level are eligible to apply for a research starter grant. The program is not intended for individuals in post-doctoral training programs.
Applicants must be sponsored by the department within which the proposed research is to be undertaken. Applicants must be based in an academic, healthcare, or other research institution (e.g., schools of medicine, public health, pharmacy, nursing, etc) and should have the skills and experience required to carry out the proposed work. Applications are to be submitted to firstname.lastname@example.org and received by May 16, 2014.
The award consists of $100,000 support for one year and is made to the university or institution on behalf of the recipient, with the understanding that the university or institution will administer the funds. The “starter” aspect of the program strives to assist individuals who are establishing careers as independent investigators with an interest in describing the benefits of cancer treatment, innovation, and progress. The funds are to be used to conduct the proposed research and provide the grantee financial support to promote future research efforts in this field. Applicants are highly encourage to seek other funds to continue research following termination of the starter grant.
Recommended guidelines for using the starter grant funds are listed below. The submitted line item budget must reflect how the funds will be used based on the guidelines:
1. The purchase data or equipment that will support the proposed research efforts.
2. The support technical assistance (e.g., technician/research assistant; not including fringe benefits).
3. No more than $1,000 may be used per year for travel to professional meetings by the grantee.
4. A percentage of the funds may be used for salary (not to exceed 25%), if the review panel determines this level of support is justified given the applicant’s current position, current funding level, and proposed research plan.
5. The program provides no other subsidies (tuition, fringe benefits, indirect institutional costs, etc).
The applicant should also identify other intramural support presently available for the proposed project and other research efforts by budget categories and amounts. If the institution makes available the services of a technician or assistant to the candidate, please note this support. Other principals involved in the project as collaborators and the amount of time developed to the project by the applicant and other principals should also be identified. Please also list by titles the funded research project of each principal, the percentage of time committed, and the amount and source of funds for these projects. Additional investigators are welcome to as collaborators in a multidisciplinary research team. The amount of time to be devoted to the project by the applicant and other co-investigators or co-applicants should be clearly described in the research proposal.
A progress report (approximately 2 pages) will be required at midterm, and a final report (approximately 10 pages) will be required upon completion of the work. The PhRMA Foundation project officer should be made aware of manuscripts to be published as a result of the proposed research. The funds are non-transferrable.
The application package must be submitted in the order listed below as a single PDF. The applicant’s name, institution, and project title should be provided as a header on the top right corner of each page. Any questions about the application or eligibility criteria should be directed to Clara Soh at email@example.com.
List of Application Components:
1. Introduction page, including applicant name, mentor name, institution, project title, and research abstract (300 word limit)
2. Applicant CV or biosketch
3. 1-page applicant cover letter describing why he/she is qualified to conduct the proposed research and how the fellowship award will provide training and education to help further his/her career. The letter should also state whether the applicant has any conflicts of interest.
4. Research plan (10 page limit, 12 point font; single spaced, with 1” margins, bibliography excluded from page limit restriction) that includes a brief abstract and comprehensive description of the research plan. Applicants are requested to include a description of the study objective(s), conceptual framework, rationale, key measures, methodology, known limitations, expected findings, and significance/potential impact of the findings. Preliminary results, if any, should also be included. The proposal should state plans for dissemination of research findings (i.e., expected peer-reviewed publications, poster, or paper presentation at research meetings).
5. Budget, with breakdown of how funds will be used and any other anticipated sources of funding
6. Reprints of relevant articles published or co-authored by applicant
7. Contact information and CV/biosketch of applicant’s mentor/dissertation chair
8. Letter of recommendation from mentor/dissertation chair (1 page limit). The proposed research should be directed under the guidance of a mentor. The mentor must provide a letter of recommendation that certifies that formal mentorship will be available to ensure adequate training of the applicant and encourage progression of the study. The letter should also describe why the applicant’s potential and experience qualifies them to conduct the proposed research. The research record of the mentor and a description of how the mentored experience will enhance the applicant’s research objective(s) should also be included. The letter should describe how often and in what setting the mentor will engage with applicant (e.g., weekly meetings). The letter should also state whether the mentor has any conflicts of interest related to the proposed research. No more than one letter of recommendation is required or permitted.
Review Process and Criteria
Applications will be judged on the scientific worthiness of the proposed research and will be evaluated by a panel of qualified reviewers selected by the PhRMA Foundation. Reviewers may offer written critiques or suggestions of the proposal; award recipients are expected to incorporate reviewer feedback into their research. The review criteria will include the following (weight included in parenthesis):
-- Potential impact of research findings (20%)
-- Study approach and methodology (20%)
-- Innovativeness (20%)
-- Potential to stimulate further downstream research (15%)
-- Research environment/mentorship (10%)
-- Generalizability (10%)
-- Feasibility (5%)
Call for Applications: Ovarian Cancer Research Fund Woman to Woman Program Grant
A Woman to Woman program grant recipient will receive a one-year grant of no more than $50,000. This grant opportunity is available to any medical institutions with a sufficient volume of gynecologic cancer patients and a need to provide this type of support service to patients. Grants are provided to cover the cost of a part-time Program Coordinator’s salary (can be a new hire, or a reassignment), program costs, and the patient fund (no indirect costs are allowed). It is expected that each Woman to Woman program will become self-funding after the first year.
OCRF will provide all program materials for patients, as well as technical assistance and support, for the life of the program (even after the end of the grant period). Programs will also have access to a dedicated section of the fund's website available to participants only, which will feature tools to assist in the development and administration of new programs.
OCRF is now accepting applications for a Woman to Woman program grant. The deadline for submission is May 1, 2014.
For questions about Woman to Woman, please email Julia Volpin at firstname.lastname@example.org.
Call for Applications: Livestrong Foundation Big C Competition
We're looking for big thinkers to create tangible innovations and solutions improving the daily lives of people facing cancer.
The Big C competition is an opportunity to change the way the world fights cancer.
How it Work
May 15 deadline for submitting your product, service or innovation.
150 semi-finalists have access to mentoring, crowdfunding and media exposure.
Five teams pitch in Austin for a chance to win $25,000!
(60 teams win a total of $140,000)
Solutions We Seek
The Big C competition invites you to submit projects addressing the following needs.
Rebuild Financial Health
Regain Emotional Wellbeing
Care for Caregivers
Improve Access to Quality Care
Fill the Knowledge Gap
Help Anyone Facing Cancer Now
Call for Applications: Alex's Lemonade Stand Foundation Reach Awards
Alex's Lemonade Stand Foundation (ALSF) evolved from the front yard lemonade stand of cancer patient Alexandra “Alex” Scott (1996-2004) into a national fundraising movement to raise awareness and find cures for all childhood cancers.
Reach Awards are designed to move hypothesis-driven research toward the clinic. A successful application will identify an unmet clinical need relevant to the care of patients with pediatric cancer and describe how the work performed will allow for the translation of hypothesis-driven research to the clinic keeping broader clinical testing and implementation in view.
All Reach Award applications must be received by May 30, 2014 - 11:59 PM ET.
Maximum of $250,000 in total costs awarded over two years.
All applications must be submitted using ALSF’s online submission process.
The purpose of the Reach Award is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Award seeks to remove one of these barriers by providing support for important pre-clinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support selected “late translational” studies needed to ultimately initiate a clinical trial. Preference will be given to those research projects which, if funded, will result in the initiation of a clinical trial within two to three years.
Primary applicants may be Assistant, Associate or Professor level investigators who demonstrate a track record of discovery, investigation and external funding. Applicants may be M.D., D.O., Ph.D, or M.D./Ph.D. Applicants must have a demonstrated track record of pediatric cancer research with experience in translational research Multiple investigator applications that bring together pairs or teams of researchers with complementary expertise are encouraged. Phase I/II Trials are not eligible for funding by this grant mechanism.
Call for Applications: Alex's Lemonade Stand Foundation ‘A’ Awards
The ‘A’ Award is a three-year grant designed for the early career scientist who wants to establish their career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of outstanding mentorship and a future commitment to pediatric cancer investigation are critical components of a successful application. Institutional commitment to the career of the applicant is also expected.
All applications must be received by May 23, 2014 - 11:59 PM ET.
This award totals $450,000 over three years and is open to MD, MD/PhD and PhD candidates.
‘A’ Award Program Goals To encourage the best and brightest early career researchers to build lifelong careers and become leaders in the field of pediatric cancer research. To advance research that will lead to new treatments and cures impacting children with cancer.
Highlights NEW in 2014: ALSF increased the award to $450,000 over 3 years ($150,000 per year) Recipient will have the opportunity to speak at and attend Foundation events In addition to the grant funds, the "A‟ Award provides
-- reference books to enhance personal pediatric oncology library
-- equipment to enhance lab/project work up to $10,000
-- registration fees for one educational course or event
Eligibility Criteria (Updated for 2014!) Proposals must be aligned with ALSF's mission and "A‟ Award program goals. Applicants must have an M.D., Ph.D. or dual M.D., Ph.D. (D.O., MBBS or equivalent) and must not have achieved an appointment higher than assistant professor. In addition,
-- M.D. and M.D., Ph.D. Applicants
o M.D. or M.D., Ph.D. applicants must be no more than 6 years after finishing 3-year fellowship at the time the award would start (i.e. fellowship ended in 2008 or later) and be no more than 12 years since receiving the most recent professional degree (Ph.D, M.D., D.O., MBBS or equivalent) at the time the award would start. Preference will be given to applicants no more than 12 years since receiving the first professional degree.
o M.D. candidates who did not have a 3-year fellowship must have 3 years of research experience after M.D. was awarded and be no more than 12 years since receiving the M.D. at the time the award would start.
-- Ph.D. Applicants
o Ph.D. applicants must be no more than 6 years since being awarded Ph.D. (i.e., if Ph.D. is awarded in 2008 or later, applicant is eligible for 2014 "A‟ Award). A minimum of 75% of the applicant's time during "A‟ Award must be allocated as protected time for all research activities. Applicants holding K99/R00, R01 are not eligible.
Applicants MAY have research grants from other funding sources during the "A‟ Award period, but there must be clear documentation of mechanisms to avoid scientific and budgetary overlap. Current ALSF Grant Recipients
-- Applicants currently holding an ALSF 2012 Young Investigator Award, ending June 30, 2014, are eligible to apply.
-- Applicants currently holding an ALSF 2013 Young Investigator Award or are Center of Excellence Scholars are not eligible.
-- Applicants currently holding ALSF's Innovation, Reach, Phase I/II Infrastructure or Epidemiology grants are not eligible to apply for the 2014 "A‟ Award. Prior Young Investigator applicants: If you are submitting a Young Investigator application previously reviewed but not funded by ALSF for the "A‟ Award, you must complete the resubmission section: respond to critiques, describe changes and/or new data etc. A detailed mentoring plan for career development must be clearly articulated with appropriate letters of support. Institutional commitment to the applicant's career must be addressed. Funds must be granted to nonprofit institutions or organizations operating in the United States or Canada. Researchers need not be U.S. citizens.
Resubmissions: Only one resubmission of a previously reviewed "A‟ Award or Young Investigator proposal is permitted.
Call for Applications: American Gastroenterological Association-Aptalis Research Award in Pancreatic Disease
Eligibility: Young Investigators
Duration: Two years
Deadline: June 6, 2014
Start Date: Oct. 1, 2014
This award provides $50,000 per year for two years (total $100,000) to young investigators, instructors, research associates or equivalents interested in the function and disorders of the exocrine pancreas. Research topics suitable for funding under this grant include but are not limited to: pancreatitis, pancreatic cancer, pancreatic insufficiency, the gut microbiome-pancreas relationship, pancreatic disease epidemiology or genetics (excluding diabetes), and pancreatic disease biomarkers.
The overall objective of this career development award is to encourage and support research into exocrine pancreatic disorders by helping to sustain the careers of young investigators with an interest in pancreatic disease.
• Candidates for this award must hold an MD, PhD or equivalent degree (e.g., MB, ChB, MBBS, DO) and a full-time faculty position at a North American institution by June 1, 2014.
• AGA membership is required at the time of application submission. Please visit the membership page or call 301-654-2055, extension 651, for membership information.
• The award is intended to support young faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research. Candidates should be in the beginning years of their careers; therefore, established investigators are not appropriate candidates.
• MD applicants: no more than seven years shall have elapsed following the completion of clinical training (GI fellowship or its equivalent) and the start date of this award.
• PhD applicants: no more than seven years shall have elapsed following the awarding of a PhD and the start date of this award.
• Women and underrepresented minority applicants are strongly encouraged to apply; these applications in particular will receive the review committee’s full consideration.
• An appropriately documented parental leave of absence will not be counted toward the above noted seven-year eligibility criteria. Exceptional circumstances may also be considered.
• All submissions must be relevant to diagnosing, treating or researching the functions or diseases of the exocrine pancreas.
• At the time of application submission, candidates may not hold or have held an NIH R01, R29, R21, K08, K23, Veterans Affairs Career Development Award or any award with similar objectives from non-federal sources (such as the American Liver Foundation, Burroughs Wellcome Fund, Crohn’s and Colitis Foundation of America, Robert Wood Johnson Foundation, etc.). Candidates with an active K12 may apply.
• The intent of this award is to foster the scientific independence of junior investigators. It is understood that there may be some overlap with work funded by the mentor, but the goal of this grant is to enable the junior investigator to develop their own research program. It also must be clearly stated that the work submitted by the applicant is primarily that of the applicant, and any work or data from the senior mentor’s laboratory clearly defined.
• Resources allocated through this award are intended to support the career development of the applicant. Accordingly, requests for salary, fringe benefits or other support for the mentor are not allowed. Indirect costs are not allowed. Upon notification of receipt of this award, the recipient must provide institutional approval from the appropriate committee for use of human subjects or animals. If approval is not necessary, the recipient must provide an explanation. Evidence for developing independence in research initiatives should be provided.
• Candidates are required to have a sponsor and preceptor for the award; however, one individual may serve in the capacity of both positions. A sponsor is an individual who takes responsibility for the quality assessment of the proposed research project, the quality of the research environment within which the project will be undertaken, and the experience and expertise of the principal investigator and other key researchers involved. A preceptor will supervise the principal investigator’s research activities and will serve as a mentor.
• Annually, a one-page plain language progress report, a scientific progress report, a financial statement, a list of publications based on the research and a letter of certification from the division chief or department chair, must be submitted by the award recipient by Nov. 30. Second year funding is contingent upon submission of this documentation. All publications, presentations and abstracts arising from work funded by this program must acknowledge support of the AGA-Aptalis Research Award in Pancreatic Disease.
There must be a strong commitment from the candidate’s institution to support the required protected time for research and adequate laboratory space and/or other supporting facilities. These commitments must be outlined in a letter from the candidate’s division chief or department chair. The letter must certify that the award is being used to provide protected time, in accord with the terms of the award. In addition, it is expected that the sponsor will outline specific plans for the future development of the candidate’s research career. The institution must commit to ensuring timely and accurate reporting of the awardee’s current and future research activities at the institution; this is to include an annual report of the funding status, grants submitted and pending, and all publications.
The recipient will be selected based on the following criteria: significance, investigator, innovation, approach, environment, relevance to AGA’s mission and evidence of institutional commitment. The candidate should state clearly how the additional training will benefit his/her research career.
A selection committee comprised of members of the AGA Research Awards Panel will review the proposals and select the award recipients. Funding will commence October 2014.
The application deadline is June 6, 2014. The completed application, letters of support or commitment and other documents, as applicable, must be combined into and submitted as one PDF document. The document must be titled by the applicant’s last name and first initial only. Hard copies are not accepted. Please email the application document to email@example.com. Direct all questions to the research awards manager via telephone at 301-222-4012 or email at firstname.lastname@example.org.
Funding for this award is provided by Aptalis Pharma US, Inc.
Lung Cancer Research Foundation Grant Program
Deadline: Friday, June 16, 2014
The Lung Cancer Research Foundation's grant program provides critical seed support for cutting-edge scientific research on all cancers of the lung. We believe this type of support can build proof of concept for researchers to apply for additional grant funding from universities and public sources.
LCRF GRANTS ARE AWARDED FOR LUNG CANCER PROJECTS FOCUSED ON:
• Basic Science
• Translational Research
• Clinical Research
• Supportive Care
• Quality of Care/Outcomes
LCRF PROVIDES FUNDS TO U.S. AND INTERNATIONAL INVESTIGATORS FROM NOT FOR PROFIT INSTITUTIONS:
• Graduate students
• Post-doctoral researchers
• Medical students
• Nurse researchers
North American Neuroendocrine Tumor Society Clinical Investigator Scholarship
Deadline for submission of the application is June 30, 2014 (11:59 pm PDT).
The purpose of the NANETS Clinical Investigator Scholarship is to encourage clinicians at the end of their fellowship or beginning of their faculty appointment to pursue a clinical career focused on neuroendocrine tumors.
Award Term: The NANETS Clinical Investigator Scholarship will provide $50,000 per year for one year. Award funds will be directed to the sponsoring institution. At the conclusion of the award period, the recipient must provide NANETS with a written progress report of the project performed during the award period and a budget reconciliation.
• Candidates must have a MD, MD/PhD, DO degree or equivalent
• Candidates must be in the first 5 years of a faculty appointment (instructor or above) in an accredited medical school or other institution in North America (must be on staff at time of award)
• Candidates must be a NANETS member
Selection Criteria: Criteria for selection will include both the clinical project itself and the potential of the individual to make future clinical contributions to the neuroendocrine tumor field. Strong emphasis will be placed on the career development plan and the applicant’s personal statements and the mentor’s development plan. The clinical proposal section should focus on a project with the potential to directly impact and improve the treatment of patients with neuroendocrine tumors. Appropriate projects would include (but are not limited to) correlative studies involving existing clinical trials, retrospective studies, a NET database, risk factors and/or any project with a clear clinical significance.